Home
Clinical Trials
Partnerships
Contact Us
News & Resources
Careers
About Us
Management Team
Board of Directors
Scientific and Clinical Advisory Boards
Commercial Advisory Board
Our Focus
Infectious Disease
Oncology
Our Pipeline
Prophylactic
Therapeutic
Clinical Trials
Publications
Early/Expanded Access Policy
Our Science and Technology
Investors
Press Releases
Events and Presentations
Company Information
Stock Information
SEC Filings
Corporate Governance
About Us
Management Team
Board of Directors
Scientific and Clinical Advisory Boards
Commercial Advisory Board
Our Focus
Infectious Diseases
Oncology
Our Pipeline
Prophylactic
Therapeutic
Clinical Trials
Publications
Early/Expanded Access Policy
Our Science and Technology
News and Resources
News
Posters
Publications
Videos
Investors
Press Releases
Company Information
Corporate Governance
Events and Presentations
SEC Filings
Stock Information
Careers
Partnerships
Contact Us
Search our website
Glioblastoma (“GBM”)
VBI Vaccines Granted FDA Fast Track Designation for VBI-1901 for the Treatment of Recurrent GBM
June 8th, 2021
VBI Vaccines to Present Updated Phase 2a Tumor Response and Overall Survival Data for VBI-1901 in Recurrent GBM at 2021 ASCO Annual Meeting
May 20th, 2021
VBI Vaccines Announces Positive Interim Phase 2a Data from VBI-1901 in Recurrent GBM
November 19th, 2020
VBI Vaccines Announces e-Poster Presentation at the Society for Neuro-Oncology (SNO) 2020 Virtual Meeting
November 9th, 2020
VBI Vaccines to Present at Upcoming Scientific Conferences
September 24th, 2020
VBI Vaccines Announces Biomarker Data from VBI-1901 Phase 1/2a Study in Recurrent GBM Presented at ESMO Virtual Congress 2020
September 17th, 2020
VBI Vaccines to Present Additional Biomarker Data from VBI-1901 Phase 1/2a Study in Recurrent GBM in an E-Poster at ESMO Virtual Congress 2020
September 14th, 2020
VBI Vaccines Announces Data from VBI-1901 Presented at AACR 2020: Partial Response Observed, Promising Biomarker Strategy Identified
June 22nd, 2020
VBI Vaccines Announces Upcoming Poster Presentation of Phase 1/2a data of VBI-1901 in Recurrent GBM Patients at AACR Virtual Annual Meeting
May 15th, 2020
VBI Vaccines Provides Update on Part A of Ongoing Phase 1/2a Study Demonstrating Overall Survival Benefit for VBI-1901 Vaccine Responders in Recurrent GBM Patients
March 3rd, 2020
VBI Vaccines Announces Dosing of First Recurrent GBM Patient in Phase 2a Study of Cancer Vaccine Candidate, VBI-1901, in Combination with GSK’s AS01B Adjuvant System
March 2nd, 2020
VBI Vaccines Presents Early GBM Tumor Response and Immunologic Data from Part B of Ongoing Phase 1/2a Study of VBI-1901 at the 2019 SNO Annual Meeting
November 22nd, 2019
VBI Vaccines to Present Initial Phase 1/2a Part B Data of VBI-1901 at the 2019 Society for Neuro-Oncology (SNO) Annual Meeting
November 11th, 2019
VBI Vaccines to Present New Immuno-Oncology Data at the World Vaccine Congress Europe 2019
October 24th, 2019
VBI Vaccines Announces Phase 2a Clinical Evaluation of VBI-1901 Cancer Vaccine Candidate in Combination with GSK’s AS01B Adjuvant System in Recurrent Glioblastoma Patients
September 10th, 2019
VBI Vaccines Announces Dosing of First Recurrent GBM Patient in Part B of Ongoing Phase 1/2a Study of VBI-1901
July 29th, 2019
VBI Vaccines Reports Data from Part A of the Ongoing Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients at ASCO 2019
June 4th, 2019
VBI Vaccines Provides Update on GBM Program and Announces Upcoming Conference Call
April 23rd, 2019
VBI Vaccines Announces Poster Presentation at the 7th International Congenital CMV Conference & 17th International CMV Workshop
April 3rd, 2019
VBI Vaccines Provides Corporate Update, Outlook for 2019, and Year-End 2018 Financial Results
February 25th, 2019
Page 1 of 3
1
2
3
›
Sign-up for Our Distribution List to Receive the Latest News and Updates from VBI
Sign Up Now
